measurements of a sequence common to several targets.

The method's software design allows for large (>10,000) target sets and large probe set sizes (2->1,000,000). While current selection criteria involve a time consuming iterative and manual process, the present invention allows for the identification of a quantitatively optimized probe set which balances probe performance criteria and simultaneously optimizes the sensitivity and specificity of the assay for a given set of targets.

Applications: The invention has applications in the design of various important assays, such as those based on microarrays, multiplexed PCR and SPR, targeted protein fragment detection, or any sequence-specific binding and detection. It has application where the number of probes to be used in an assay is too large for manual design and review.

*Inventors:* Eric Billings and Kevin E. Brown (NHLBI).

Patent Status: U.S. Provisional Application No. 60/871,447 filed 21 Dec 2006, entitled "Probe Set Global Optimization" (HHS Reference E–332– 2005/0–US–01).

Development Status: The technology is ready to be applied and validated in many different areas for research and diagnostic purposes.

*Licensing Status:* Available for nonexclusive or exclusive licensing.

*Licensing Contact:* Cristina Thalhammer-Reyero, Ph.D., M.B.A.; 301/435–4507; *thalhamc@mail.nih.gov.* 

Collaborative Research Opportunity: The National Heart, Lung and Blood Institute, Computational Biophysics Laboratory is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, utilize or commercialize a method for optimizing sequence-based assays. Please contact Dr. Eric Billings, at (301) 496–6520 or via e-mail at *billings@helix.nih.gov* for more information.

Dated: August 16, 2007.

# Steven M. Ferguson,

Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. E7–16644 Filed 8–22–07; 8:45 am]

BILLING CODE 4140-01-P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### National Institutes of Health

#### National Eye Institute; Notice of Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the National Advisory Eye Council.

The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Advisory Eye Council.

*Date:* September 27, 2007.

Closed: 8:30 a.m. to 10:30 a.m. Agenda: To review and evaluate grant applications and/or proposals.

*Place*: National Institutes of Health, 5635 Fishers Lane, Terrace Level Conference Center, Bethesda, MD 20982.

*Open:* 10:30 a.m. to Adjournment. *Agenda:* Following opening remarks by the Director, NEI there will be presentations by the staff of the Institute and discussions concerning Institute programs.

*Place:* National Institutes of Health, 5635 Fishers Lane, Terrace Level Conference Center, Bethesda, MD 20892.

*Contact Person:* Lore Anne McNicol, PhD, Director, Division of Extramural Research, National Eye Institute, National Institutes of Health, Bethesda, MD 20892, (301) 451–2020.

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

Information is also available on the Institutes's/Center's home page: *http:// www.nei.nih.gov*, where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.867, Vision Research, National Institutes of Health, HHS) Dated: August 14, 2007. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. 07–4100 Filed 8–21–07; 8:45 am] BILLING CODE 4140–01–M

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

## National Institutes of Health

Supplementary Risk Assessments and Site Suitability Analyses for the National Emerging Infectious Disease Laboratory, Boston University Medical Center

**ACTION:** Availability of Supplementary Risk Assessments and Site Suitability Analyses for the National Emerging Infectious Disease Laboratory, Boston University Medical Center; notice of hearing.

SUMMARY: The National Institutes of Health (NIH) has placed in the docket for public review and comment the Supplementary Risk Assessments and Site Suitability Analyses for the National Emerging Infectious Disease Laboratory, Boston University Medical Center, which address additional concerns of the local community regarding possible impacts of the National Emerging Infectious Diseases Laboratory, Boston University Medical Center. The purpose of the Supplementary Risk Assessments and Site Suitability Analyses for the National Emerging Infectious Disease Laboratory was alternative site analysis and risk assessment that investigated potential infectious disease threats that may be posed to the public should an exotic infectious agent be released into the community through an infected laboratory worker, laboratory accident, or other mishap.

DATES: Comments on the Supplementary Risk Assessments and Site Suitability Analyses for the National Emerging Infectious Disease Laboratory must be received by Monday, November 12th. A public hearing will be held on Thursday, September 20, 2007, from 7–9 p.m. at Faneuil Hall, Dock Square, Boston, MA 02109.

ADDRESSES: Comments should be sent to Valerie Nottingham, Division of Environmental Protection, National Institutes of Health, 9000 Rockville Pike, Building 13, Room 2S11, Bethesda, MD 20892, MSC 5746. E-mail comments should be sent to *nihnepa@mail.nih.gov.* Comments sent by e-mail must be received by 11:59